DocuSign (DOCU) Q1 2027 Margin Compression Challenges Bullish Earnings Growth Narratives

DocuSign (DOCU) has kicked off Q1 2027 with total revenue of US$830.2 million and basic EPS of US$0.40, setting the stage for investors to reassess how the business is converting its top line into earnings. The company has seen quarterly revenue move from US$763.7 million in Q1 2026 to US$830.2 million in Q1 2027, while basic EPS shifted from US$0.35 to US$0.40 over the same stretch, giving you a clear read on how sales and earnings are tracking into the new fiscal year as margins come under closer scrutiny.

See our full analysis for DocuSign.

With the latest earnings out, the next step is to see how these numbers line up with the widely held narratives around DocuSign's growth potential, profitability, and risk profile.

See what the community is saying about DocuSign

NasdaqGS:DOCU Revenue & Expenses Breakdown as at Jun 2026
NasdaqGS:DOCU Revenue & Expenses Breakdown as at Jun 2026
Advertisement

Margin picture: 9.6% net profit on US$3.3b TTM sales

  • Over the last twelve months, DocuSign generated US$3.3b of revenue and US$315.2 million of net income, which works out to a 9.6% net profit margin compared with 36.5% a year earlier.
  • Consensus narrative expects margins to work higher over time, and the current 9.6% level creates a tension with that view:
    • Analysts are modeling margin expansion to 12.1% in about three years, alongside revenue growth of 7.5% per year. The trailing margin, however, sits well below last year’s 36.5% figure.
    • This mix of modest forecast revenue growth and lower current margin means any improvement investors are watching for is not yet visible in the trailing 12 month numbers.

Valuation gap: US$47.26 vs DCF fair value of US$127.75

  • The current share price of US$47.26 sits well below the stated DCF fair value of US$127.75, and the stock trades on a 29.1x P/E compared with 28.4x for the broader US software industry and 56.8x for the peer group.
  • Bulls argue that DocuSign’s business can justify that DCF fair value, and the current metrics give them some support but also a few checks:
    • Forecast earnings growth of about 15.4% per year and expectations for margins to move up from 9.6% are consistent with the idea of higher future earnings feeding into a higher valuation.
    • At the same time, revenue growth of about 6.7% per year is below broader US market levels, so the share price discount to DCF fair value is not matched by standout top line growth in the forecasts.
On these numbers, bulls are leaning heavily on earnings growth and margin recovery to close the wide gap between price and DCF fair value, so it is worth seeing how the full bullish case ties those pieces together 🐂 DocuSign Bull Case

Forecast growth vs margin compression worries

  • Earnings are forecast to grow about 15.4% per year with revenue at about 6.7% per year, while the trailing net profit margin sits at 9.6% compared with 36.5% in the prior year.
  • Bears focus on whether this margin profile can support those growth forecasts, and the reported figures give them some talking points:
    • Critics highlight that margins have moved down sharply from last year’s 36.5% level. This lines up with concerns about pricing pressure and higher costs weighing on profitability.
    • With revenue growth forecasts below the broader US market, the company has less room for error if higher spending is needed to defend share in a competitive agreement management market.
For readers weighing these concerns, it helps to see how the cautious side connects margin pressure, competition, and those mid-teens earnings forecasts in more detail 🐻 DocuSign Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DocuSign on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both the optimism around growth and the concerns on margins, it makes sense to check the underlying data yourself and decide where you stand. To help balance those views and move quickly from headline numbers to the full picture, take a look at the 2 key rewards and 1 important warning sign

See What Else Is Out There

DocuSign’s sharp margin compression from 36.5% to 9.6%, paired with only mid single digit revenue forecasts, leaves limited room if costs or competition rise further.

If that mix of squeezed profitability and modest growth makes you cautious, it might be time to focus on companies already priced attractively with stronger fundamentals through the 49 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:DOCU

DocuSign

Provides electronic signature solution in the United States and internationally.

Excellent balance sheet and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
25 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

FE
PASS3 logo
FernandoLeal on Compass Gas e Energia ·

Compass Gas e Energia has a reliable dividend, with a consistent moat, high free cash flow margins and will expand to two digits net margin.

Fair Value:R$40.9438.2% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
84 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
192 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0